12 results about "Immunomodulin" patented technology

Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.

This invention relates to APRIL and BAFF inhibitory immunomodulatory proteins and methods of using them, specifically providing immunomodulatory proteins exhibiting neutralizing activity against BAFF and APRIL (or BAFF / APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of transmembrane activators and CAML interactors (TACI). The provided immunomodulatory proteins include TACI-Fc fusion proteins. Nucleic acid molecules encoding said immunomodulatory proteins are also provided. The immunomodulatory proteins provide therapeutic efficacy against a variety of immune diseases, disorders, or conditions. Compositions and methods for preparing and using such proteins are also provided.

The invention discloses application of ganoderma lucidum immunomodulatory protein in preparation of a product for targeting TK1, and belongs to the technical field of biological medicine. The protein can be directly combined with a tumor proliferation marker TK1, and the expression level of TK1 is reduced, so that tumor cell proliferation is inhibited. The invention discloses a molecular mechanism that ganoderma lucidum immunomodulatory protein plays an anti-tumor role through targeting TK1 for the first time, and specifically discloses an amino acid site of the ganoderma lucidum immunomodulatory protein interacting with TK1. Based on the discovery, the invention also provides food, health-care food or medicine which contains the ganoderma lucidum immunomodulatory protein and is used for inhibiting TK1 or tumors, and the food, health-care food or medicine is particularly suitable for preventing and treating breast cancer. The invention provides a new direction for clinical application transformation of the ganoderma lucidum immunomodulatory protein, and has important development value and application prospect.

Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF / APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.

The invention relates to the technical field of biological medicine, and discloses a preparation method of ginseng protein peptide for immunomodulation.The preparation method comprises the following steps of raw material pretreatment, saponin removal and desugaring treatment, protein extraction and denaturation, directional enzymolysis, inactivation and separation, refining and drying; a compound enzyme preparation containing cellulase, pectinase and beta-glucosidase is adopted to carry out directional desugaring treatment on ginseng powder subjected to saponin removal, non-target carbohydrate impurities combined with protein can be removed, sugar residues in subsequent products are reduced, and therefore pure desugaring protein powder is obtained to serve as an initial raw material, and the yield of the ginseng powder is improved. A foundation is laid for subsequent preparation of the high-activity immunomodulatory protein peptide; ultrasonic assistance is introduced, and a real-time hydrolysis degree monitoring and regulation strategy is coupled, so that the enzymolysis reaction is more uniform; through on-line monitoring and dynamic intervention on the hydrolysis degree, the enzymolysis process can be stabilized in a preset optimal peptide fragment generation interval, and the strong effect and stability of the immunomodulatory activity of the final product are guaranteed.